Sponsored by
Amazing long term data presented for the phase 1 trial of ict-107. This was a small trial (16 patients) for newly diagnosed gbm patients. Results:19% of patients had long-term remission of greater than 8 years. Also, 38% of patients demonstrated long-term survival of greater than 8 years. At the time the trial started, expected survival was less than 18 months for standard treatments. A subsequent larger trial showed early results that was good but not this good. Hopefully as the data matures, the tail of long term survivors will jack up the average survivals! This is a relatively simple treatment with minimal side effects.
http://www.streetinsider.com/dr/news.php